Edesa Biotech Inc (EDSA) - Total Liabilities
Based on the latest financial reports, Edesa Biotech Inc (EDSA) has total liabilities worth $2.19 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore EDSA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Edesa Biotech Inc - Total Liabilities Trend (2008–2025)
This chart illustrates how Edesa Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See Edesa Biotech Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Edesa Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Edesa Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mink Therapeutics Inc
NASDAQ:INKT
|
USA | $28.48 Million |
|
Phosco Ltd
AU:PHO
|
Australia | AU$9.60 Million |
|
NextBoat Inc.
NYSE MKT:NXB
|
USA | $53.99 Million |
|
Il Sung Const
KO:013360
|
Korea | ₩305.56 Billion |
|
Carnival Industrial Corp
TW:1417
|
Taiwan | NT$468.63 Million |
|
Rama Phosphates Limited
NSE:RAMAPHO
|
India | Rs2.41 Billion |
|
Cenit Co. Ltd
KQ:037760
|
Korea | ₩124.74 Billion |
|
FarGlory Hotel Co Ltd
TW:2712
|
Taiwan | NT$624.43 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Edesa Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Edesa Biotech Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Edesa Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Edesa Biotech Inc (2008–2025)
The table below shows the annual total liabilities of Edesa Biotech Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $1.08 Million | -41.15% |
| 2024-09-30 | $1.83 Million | -0.48% |
| 2023-09-30 | $1.84 Million | -15.69% |
| 2022-09-30 | $2.18 Million | +43.11% |
| 2021-09-30 | $1.53 Million | -63.05% |
| 2020-09-30 | $4.13 Million | +794.91% |
| 2019-09-30 | $461.63K | -6.44% |
| 2018-09-30 | $493.38K | +53.73% |
| 2017-09-30 | $320.95K | -48.54% |
| 2016-09-30 | $623.64K | -73.80% |
| 2015-09-30 | $2.38 Million | -64.85% |
| 2014-09-30 | $6.77 Million | -41.88% |
| 2013-09-30 | $11.65 Million | +1583.58% |
| 2012-09-30 | $692.27K | +335.01% |
| 2011-09-30 | $159.14K | -62.17% |
| 2010-09-30 | $420.61K | -273.47% |
| 2009-09-30 | $-242.47K | -2688.60% |
| 2008-09-30 | $9.37K | -- |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more